Search results
Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. via Yahoo Finance· 4 days agoKaryopharm Therapeutics (NASDAQ:KPTI) First Quarter 2024 Results Key Financial Results Revenue:...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript May 8, 2024 Karyopharm...
Karyopharm Therapeutics: Q1 Earnings Snapshot
Associated Press Finance via Yahoo Finance· 6 days agoNEWTON, Mass. (AP) — NEWTON, Mass. (AP) — Karyopharm Therapeutics Inc. (KPTI) on Wednesday reported a loss of $37.4 million in its first quarter. On a per-share basis, the ...
Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
GuruFocus.com via Yahoo Finance· 6 days agoPositive Points Karyopharm Therapeutics Inc (NASDAQ:KPTI) reported a strong start to the year, advancing its late-stage pipeline with potential to set new standards of care ...
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending...
FOX 23 News Albany· 6 days agoKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced today that it has entered into a series ...
Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Det
Guru Focus· 6 days agoKaryopharm Therapeutics Inc (KPTI, Financial), a leader in the development of novel cancer therapies, disclosed its financial outcomes for the first quarter of 2024 on May ...
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
FOX 23 News Albany· 6 days ago– Announces Significant Refinancing Transactions and Amends Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and 2029, Well Beyond Expected ...
